The microtubule-associated protein Tau is an integral component of axon formation and neuronal transport, and serves as a substrate for multiple cellular signaling pathways. However, in several neurological disorders, tau loses its normal function and begins to accumulate into various types of pathological inclusions. Tau pathology and the accumulation of abnormally phosphorylated Tau species is a primary histopathologic hallmark of AD. Although some efforts have aimed to prevent Tau aggregation, a more beneficial AD treatment may be to enhance Tau clearance. Targeting the microtubule-associated protein Tau, therefore, has the potential to be the most effective strategy for treating AD.We have identified an opportunity to study and repurpose, the single enantiomer, of an FDA-approved anthelmintic drug for use in AD. The strategy will involve the preparation of the active enantiomer, pharmacokinetics of the single enantiomer, and proof of concept studies to establish a dose proportional decrease in Tau levels in the brain and cerebrospinal fluid (CSF).